Why Farbe Firma is the Top Manufacturer of Methylergonovine Maleate Injection
- Maulik Sudani
- 15 hours ago
- 8 min read
Last Updated: June 21, 2026
TL;DR: Methylergonovine Maleate Injection — a sterile, clear, colourless aqueous solution of methylergonovine (methylergometrine) maleate, a semi-synthetic ergot alkaloid uterotonic that directly stimulates uterine smooth muscle to produce a rapid, sustained contraction, supplied commonly as a 0.2 mg/mL solution in a 1 mL amber ampoule given intramuscularly or, in emergencies, by slow intravenous injection — is an essential obstetric medicine for the active management of the third stage of labour and for the prevention and treatment of postpartum and post-abortion haemorrhage caused by uterine atony or subinvolution. Because postpartum haemorrhage is a leading cause of maternal death, the strength is very low and the molecule is an oxidation- and light-sensitive ergot alkaloid that usually requires cold-chain storage, each ampoule must deliver an exact, sterile, particulate-free dose at the labelled strength, with the assay, the ergot-related-substance and oxidative profile, antioxidant and pH control, an inert-gas headspace, fill volume, low particulate and endotoxin, a validated sterilisation route, light-protective and refrigerated packaging and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Methylergonovine Maleate Injection at our Gujarat, India facility and supplies it to obstetric, maternity, emergency and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Semi-synthetic ergot alkaloid uterotonic / oxytocic (methylergonovine — methylergometrine — maleate) — Methylergonovine Maleate Injection directly stimulates uterine smooth muscle to produce a rapid, sustained contraction for the active management of the third stage of labour and the prevention and treatment of postpartum and post-abortion haemorrhage from uterine atony or subinvolution, where an exact, immediately available, reproducible dose is critical to maternal survival.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated light-protected and nitrogen-purged compounding and ampoule filling lines, control of the stability-indicating assay, the ergot-related-substance and oxidative profile, antioxidant content, solution pH, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, validated cold-chain (2–8 °C) stability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, maternal-health-programme and institutional tenders.
End-to-end CDMO services: Sterile-solution amber-ampoule contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, cold-chain-ready tamper-evident tender packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Methylergonovine Maleate Injection Demands a Premium Manufacturer
Methylergonovine Maleate Injection holds a critical, time-sensitive place in labour wards, maternity units, operating theatres and emergency departments across every market. It is the uterotonic clinicians reach for when the uterus fails to contract after delivery — to clamp down the muscle and the placental-site blood vessels in the active management of the third stage of labour, and to prevent and treat the postpartum and post-abortion haemorrhage that follows uterine atony or subinvolution. Postpartum haemorrhage remains one of the leading causes of maternal mortality worldwide, so a reliable, fast-acting uterotonic is a true maternal-health essential medicine. As a semi-synthetic ergot alkaloid that directly stimulates uterine smooth muscle to produce a rapid, sustained tetanic contraction, methylergonovine acts within minutes when given intramuscularly and within seconds when given by slow intravenous injection in a life-threatening bleed. In every one of these settings the dose delivered from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, because a clinician managing an obstetric emergency depends on a precise, ready, reproducible dose given without a moment's delay.
That clinical reality places exceptional demands on the manufacturer. Methylergonovine Maleate Injection is a very low-strength aqueous solution — 0.2 mg in a 1 mL ampoule — so the assay must be exact at sub-milligram concentration and the fill volume accurate so each tiny unit delivers the labelled dose. Above all, methylergonovine is an ergot alkaloid, a chemical class that is intrinsically oxidation- and light-sensitive and prone to degradation on exposure to heat: exposed to light, oxygen or warmth it loses potency and can form ergot-related degradation products, which is why the product is typically stored refrigerated at 2–8 °C and protected from light. To defend it, the manufacturer must compound at a controlled, slightly acidic pH, add an antioxidant where appropriate, purge and blanket the solution and headspace with an inert gas to exclude oxygen, run a validated ICH Q1B photostability programme, generate validated cold-chain stability data and package in light-protective amber glass. The solution must be free of visible and sub-visible particulates and low in endotoxin, the fill volume accurate, the route and contraindication warnings (hypertension, pre-eclampsia, pregnancy before delivery) clear on the label, and the right sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — selected and validated. Choosing a Methylergonovine Maleate Injection manufacturer that treats the stability-indicating assay, ergot-related-substance and oxidation control, photostability and cold-chain control, antioxidant and pH control, fill-volume accuracy, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Methylergonovine Maleate Injection Manufacturer Apart
A world-class manufacturer of Methylergonovine Maleate Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of methylergonovine maleate with ergot-related-substance and oxidative-degradation control by validated HPLC — accurate even at the very low 0.2 mg/mL strength — that a life-saving obstetric uterotonic demands, a robust, validated, light-protected and oxygen-excluding sterilisation and fill process backed by cold-chain stability data that protects sterility, colour, pH and clarity in an intensely labile solution, and tender-ready dossier support for an essential maternal-health medicine procured at scale through pharmacy, maternal-health-programme and ministry-of-health channels. It starts with the active — pharmacopoeial-grade methylergonovine (methylergometrine) maleate sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the colour, the pH and the oxidative stability of an exquisitely sensitive low-strength solution. The bulk solution is compounded in water-for-injection at the controlled, slightly acidic pH that keeps methylergonovine maleate stable, with an antioxidant where appropriate, under a continuous inert-gas (nitrogen) purge that strips dissolved oxygen, then sterile-filtered through 0.22 µm membrane and filled into amber ampoules under ISO Class 5 conditions with a nitrogen headspace overlay and the workflow shielded from light, with the validated sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity, colour and particulate defects; in-process and release testing confirm the assay of methylergonovine maleate by validated HPLC, the ergot-related-substance and oxidative-degradation profile, antioxidant content, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for parenteral administration. Because methylergonovine is so oxidation- and light-sensitive and the strength is so low, assay accuracy, related-substance control, photostability, cold-chain stability, light-protective packaging and container-closure integrity are validated together so the assay, colour and clarity stay within specification across shelf life.
Quality Systems Behind Every Methylergonovine Maleate Injection
Every Farbe Firma Methylergonovine Maleate Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of methylergonovine maleate against pharmacopoeial reference standards, control of ergot-related substances and oxidative-degradation products by HPLC, antioxidant content where applicable, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the amber ampoule format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated light-protected, nitrogen-blanketed filling lines with 100 % inspection, cold-chain handling and monitoring, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because methylergonovine maleate injection is an ultra-low-strength, oxidation- and light-sensitive ergot-alkaloid uterotonic and the assay, colour, ergot-related-substance and oxidative profile, antioxidant content, pH, particulate and endotoxin burden drive both efficacy and safety, we treat the stability-indicating assay, the ergot-related-substance and oxidative-degradation profile, the antioxidant content, the solution pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term and accelerated ICH Q1A conditions, under refrigerated (2–8 °C) cold-chain conditions, and with a full ICH Q1B photostability challenge, so the assay, colour, clarity and pH stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Methylergonovine Maleate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad obstetric, maternal-health and emergency small-volume parenteral portfolio. For Methylergonovine Maleate Injection specifically, we supply the 0.2 mg/mL solution in the 1 mL amber ampoule presentation under WHO-GMP conditions, with country-specific strengths, fill configurations, light-protective and cold-chain-ready tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, ergot-related-substance, antioxidant, pH, photostability, cold-chain, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender and maternal-health-programme procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, validated cold-chain stability data, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork — including route (intramuscular versus slow intravenous), protect-from-light and refrigeration handling, and contraindication warnings for hypertension, pre-eclampsia and pregnancy before delivery — for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate cold-chain shipping and logistics to the destination market. When a buyer needs Methylergonovine Maleate Injection at tender or programme scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and cold-chain shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development at very low strength, ergot-related-substance and oxidative-degradation control, antioxidant and pH formulation design, inert-gas, light-protective and cold-chain process and packaging engineering, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a life-saving obstetric uterotonic where assay accuracy, photostability and cold-chain control and dose precision directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Methylergonovine Maleate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Methylergonovine Maleate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated light-protected and nitrogen-purged compounding and amber-ampoule filling lines, validated sterilisation, cold-chain handling, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Methylergonovine Maleate Injection do you supply?
Our standard presentation is the 0.2 mg/mL solution of methylergonovine (methylergometrine) maleate in a 1 mL amber ampoule, given intramuscularly or by slow intravenous injection in emergencies. Custom strengths, fill configurations, ampoule formats, light-protective and cold-chain-ready tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Methylergonovine Maleate Injection mainly used for?
Methylergonovine Maleate Injection is used for the active management of the third stage of labour and for the prevention and treatment of postpartum and post-abortion haemorrhage caused by uterine atony or subinvolution. It is a semi-synthetic ergot alkaloid uterotonic that directly stimulates uterine smooth muscle; Farbe Firma verifies the assay, ergot-related-substance and oxidative profile, antioxidant content, pH, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Methylergonovine Maleate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, validated cold-chain stability data, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations, essential-medicines listing and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Methylergonovine Maleate Injection contract manufacturing?
MOQs vary by strength, ampoule size, sterilisation route, light-protective and cold-chain packaging, label complexity and dossier requirements. For our obstetric and maternal-health small-volume parenteral presentations we accommodate hospital-scale, national-tender-scale and maternal-health-programme orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments